Phytopharm plc Stock London S.E.
Stocks
GB0006869720
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 11-03 | WINNERS & LOSERS: Allergy Therapeutics shares plunge on AIM exit plan | AN |
| 11-02 | EARNINGS AND TRADING: Cap-XX loss narrows; GS Chain loss balloons | AN |
| Market Cap | 27.92M 36.92M 33.46M 30.94M 52.61M 3.48B 54.47M 372M 147M 1.86B 139M 136M 5.9B | P/E 2026 * |
-9.11x | P/E 2027 * | -9.81x |
|---|---|---|---|---|---|
| Enterprise Value | 17.72M 23.43M 21.23M 19.64M 33.39M 2.21B 34.57M 236M 93.55M 1.18B 87.93M 86.06M 3.75B | EV / Sales 2026 * |
2.21x | EV / Sales 2027 * | 2.42x |
| Free-Float |
89.57% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Phytopharm plc
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 19/08/2024 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 21/08/2019 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 21/08/2019 |
Katherine Rogers
BRD | Director/Board Member | 60 | 21/01/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.69% | -0.48% | +53.97% | +66.82% | 66.33B | ||
| -0.92% | +7.67% | +12.64% | +93.22% | 60.62B | ||
| 0.00% | +0.39% | +22.34% | +89.58% | 55.5B | ||
| +0.14% | +2.35% | +13.86% | +111.94% | 47.58B | ||
| -2.21% | -2.47% | +20.18% | +28.81% | 43.69B | ||
| -2.30% | -10.40% | +154.30% | +707.36% | 37.27B | ||
| +2.15% | +1.42% | +14.58% | +48.71% | 36.57B | ||
| -2.32% | -2.24% | +76.50% | +56.02% | 32.22B | ||
| +2.62% | +5.90% | -37.29% | +386.59% | 26.58B | ||
| Average | -0.61% | +0.05% | +36.79% | +176.56% | 45B | |
| Weighted average by Cap. | -0.83% | +0.20% | +36.63% | +152.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8M 10.58M 9.59M 8.87M 15.08M 997M 15.61M 107M 42.23M 533M 39.7M 38.86M 1.69B | 9M 11.9M 10.78M 9.98M 16.96M 1.12B 17.56M 120M 47.51M 599M 44.66M 43.71M 1.9B |
| Net income | -2.1M -2.78M -2.52M -2.33M -3.96M -262M -4.1M -27.96M -11.09M -140M -10.42M -10.2M -444M | -2.8M -3.7M -3.36M -3.1M -5.28M -349M -5.46M -37.28M -14.78M -186M -13.89M -13.6M -592M |
| Net Debt | -10.2M -13.49M -12.22M -11.31M -19.22M -1.27B -19.9M -136M -53.85M -679M -50.61M -49.54M -2.16B | -6.1M -8.07M -7.31M -6.76M -11.5M -761M -11.9M -81.22M -32.2M -406M -30.27M -29.63M -1.29B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
















